Moingeon P - Search Results

1

Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ. van der Burg SH, et al. Among authors: moingeon p. Clin Cancer Res. 2002 May;8(5):1019-27. Clin Cancer Res. 2002. PMID: 12006514 Clinical Trial.

2

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.

Menon AG, Kuppen PJ, van der Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ. Menon AG, et al. Among authors: moingeon p. Cancer Gene Ther. 2003 Jul;10(7):509-17. doi: 10.1038/sj.cgt.7700600. Cancer Gene Ther. 2003. PMID: 12833131

3

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. van Baren N, et al. Among authors: moingeon p. J Clin Oncol. 2005 Dec 10;23(35):9008-21. doi: 10.1200/JCO.2005.08.375. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061912 Clinical Trial.

4

Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques.

Rosenwirth B, Kuhn EM, Heeney JL, Hurpin C, Tartaglia J, Bonnet MC, Moingeon P, Erdile L. Rosenwirth B, et al. Among authors: moingeon p. Vaccine. 2001 Feb 8;19(13-14):1661-70. doi: 10.1016/s0264-410x(00)00416-3. Vaccine. 2001. PMID: 11166889

5

Therapeutic vaccines against melanoma and colorectal cancer.

Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Tartaglia J, et al. Among authors: moingeon p. Vaccine. 2001 Mar 21;19(17-19):2571-5. doi: 10.1016/s0264-410x(00)00491-6. Vaccine. 2001. PMID: 11257394 Review.

6

Recombinant viruses as a tool for therapeutic vaccination against human cancers.

Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P. Bonnet MC, et al. Among authors: moingeon p. Immunol Lett. 2000 Sep 15;74(1):11-25. doi: 10.1016/s0165-2478(00)00244-3. Immunol Lett. 2000. PMID: 10996623 Review.

7

Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.

Ullenhag GJ, Frödin JE, Mosolits S, Kiaii S, Hassan M, Bonnet MC, Moingeon P, Mellstedt H, Rabbani H. Ullenhag GJ, et al. Among authors: moingeon p. Clin Cancer Res. 2003 Jul;9(7):2447-56. Clin Cancer Res. 2003. PMID: 12855617

8

Recombinant cancer vaccines based on viral vectors.

Moingeon P. Moingeon P. Dev Biol (Basel). 2004;116:117-22; discussion 133-43. Dev Biol (Basel). 2004. PMID: 15603188

9

Cancer vaccines.

Moingeon P. Moingeon P. Vaccine. 2001 Jan 8;19(11-12):1305-26. doi: 10.1016/s0264-410x(00)00372-8. Vaccine. 2001. PMID: 11163653 Review.

10

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.

Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I. Odin L, et al. Among authors: moingeon p. Cancer Gene Ther. 2001 Feb;8(2):87-98. doi: 10.1038/sj.cgt.7700279. Cancer Gene Ther. 2001. PMID: 11263530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page